Operating
Change in receivables
Bristol-Myers Squibb Change in receivables decreased by 448.6% to -$1.69B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 11146.7%, from -$15.00M to -$1.69B. Over 3 years (FY 2021 to FY 2024), Change in receivables shows a downward trend with a -37.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryLiquidity
SignalLower is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An increase represents a use of cash, while a decrease represents a source of cash from improved collections.
Detailed definition
This metric tracks the net change in accounts and other receivables during the reporting period, reflecting the differen...
Peer comparison
Highly dependent on industry payment cycles; energy companies often see fluctuations based on seasonal demand and contract terms.
Metric ID:
change_in_receivablesHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $693.00M | $260.00M | $168.00M | -$786.00M | $669.00M | $674.00M | $106.00M | $175.00M | $65.00M | $247.00M | $508.00M | -$479.00M | $1.02B | -$661.00M | -$143.00M | -$15.00M | $484.00M | -$1.69B |
| QoQ Change | — | -62.5% | -35.4% | -567.9% | +185.1% | +0.7% | -84.3% | +65.1% | -62.9% | +280.0% | +105.7% | -194.3% | +312.7% | -164.9% | +78.4% | +89.5% | >999% | -448.6% |
| YoY Change | — | — | — | — | -3.5% | +159.2% | -36.9% | +122.3% | -90.3% | -63.4% | +379.2% | -373.7% | >999% | -367.6% | -128.1% | +96.9% | -52.5% | <-999% |
Range-$1.69B – $1.02B
CAGR+23.3%
Avg YoY Growth-717.0%
Median YoY Growth-44.7%
Change in receivables at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's change in receivables?
- Bristol-Myers Squibb (BMY) reported change in receivables of -$1.69B in Q1 2026.
- How has Bristol-Myers Squibb's change in receivables changed year-over-year?
- Bristol-Myers Squibb's change in receivables decreased by 11146.7% year-over-year, from -$15.00M to -$1.69B.
- What is the long-term trend for Bristol-Myers Squibb's change in receivables?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's change in receivables has grown at a -37.0% compound annual growth rate (CAGR), from $1.05B to -$264.00M.
- What does change in receivables mean?
- The net change in the amount of money owed to the company by customers and other parties.